Good news for those of you who suffer from cluster headaches. On June 4, the FDA announced it has approved Galcanezumab, sold as Emgality by Eli Lilly and Co., for the treatment of episodic cluster headaches.
Cluster headaches, as the name implies, occur in clusters, perhaps at the same time of day or several times a day, for weeks or months. They produce terrible pain as well as stress from knowing another will occur later. Each headache can last from 15 minutes to three hours.
Emgality reduces the frequency of the attacks. In clinical trials, patients taking the drug experienced 8.7 fewer weekly cluster headache attacks as they did before taking the drug. Those on a placebo experienced 5.2 fewer attacks.
Galcanezumab is self-injected by the patient and was originally approved by the FDA in September of 2018 for the treatment of migraines in adults.
Read more about Galcanezumab (Emgality), and if you have any questions or wonder if this treatment could be for you, contact us. We are happy to help.